Abstract
In locoregionally advanced NPC, the addition of platinum-based induction chemotherapy and cisplatin concurrent chemotherapy to radiotherapy (RT) have been consistently associated with survival benefits. Trials of adjuvant chemotherapy have yielded mixed results. The role of plasma EBV DNA in guiding the choice of induction and adjuvant chemotherapy continues to be an area of active investigation. A positive randomized study of metronomic adjuvant chemotherapy using capecitabine has offered another alternative approach for future investigations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
